Cargando…
A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol
The development of radiation countermeasures for acute radiation syndrome (ARS) has been underway for the past six decades, leading to the identification of multiple classes of radiation countermeasures. However, to date, only two growth factors (Neupogen and Neulasta) have been approved by the Unit...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796029/ https://www.ncbi.nlm.nih.gov/pubmed/29283379 http://dx.doi.org/10.3390/ijms19010079 |
_version_ | 1783297416280145920 |
---|---|
author | Cheema, Amrita K. Mehta, Khyati Y. Fatanmi, Oluseyi O. Wise, Stephen Y. Hinzman, Charles P. Wolff, Josh Singh, Vijay K. |
author_facet | Cheema, Amrita K. Mehta, Khyati Y. Fatanmi, Oluseyi O. Wise, Stephen Y. Hinzman, Charles P. Wolff, Josh Singh, Vijay K. |
author_sort | Cheema, Amrita K. |
collection | PubMed |
description | The development of radiation countermeasures for acute radiation syndrome (ARS) has been underway for the past six decades, leading to the identification of multiple classes of radiation countermeasures. However, to date, only two growth factors (Neupogen and Neulasta) have been approved by the United States Food and Drug Administration (US FDA) for the mitigation of hematopoietic acute radiation syndrome (H-ARS). No radioprotector for ARS has been approved by the FDA yet. Gamma-tocotrienol (GT3) has been demonstrated to have radioprotective efficacy in murine as well as nonhuman primate (NHP) models. Currently, GT3 is under advanced development as a radioprotector that can be administered prior to radiation exposure. We are studying this agent for its safety profile and efficacy using the NHP model. In this study, we analyzed global metabolomic and lipidomic changes using ultra-performance liquid chromatography (UPLC) quadrupole time-of-flight mass spectrometry (QTOF-MS) in serum samples of NHPs administered GT3. Our study, using 12 NHPs, demonstrates that alterations in metabolites manifest only 24 h after GT3 administration. Furthermore, metabolic changes are associated with transient increase in the bioavailability of antioxidants, including lactic acid and cholic acid and anti-inflammatory metabolites 3 deoxyvitamin D3, and docosahexaenoic acid. Taken together, our results show that the administration of GT3 to NHPs causes metabolic shifts that would provide an overall advantage to combat radiation injury. This initial assessment also highlights the utility of metabolomics and lipidomics to determine the underlying physiological mechanisms involved in the radioprotective efficacy of GT3. |
format | Online Article Text |
id | pubmed-5796029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57960292018-02-09 A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol Cheema, Amrita K. Mehta, Khyati Y. Fatanmi, Oluseyi O. Wise, Stephen Y. Hinzman, Charles P. Wolff, Josh Singh, Vijay K. Int J Mol Sci Article The development of radiation countermeasures for acute radiation syndrome (ARS) has been underway for the past six decades, leading to the identification of multiple classes of radiation countermeasures. However, to date, only two growth factors (Neupogen and Neulasta) have been approved by the United States Food and Drug Administration (US FDA) for the mitigation of hematopoietic acute radiation syndrome (H-ARS). No radioprotector for ARS has been approved by the FDA yet. Gamma-tocotrienol (GT3) has been demonstrated to have radioprotective efficacy in murine as well as nonhuman primate (NHP) models. Currently, GT3 is under advanced development as a radioprotector that can be administered prior to radiation exposure. We are studying this agent for its safety profile and efficacy using the NHP model. In this study, we analyzed global metabolomic and lipidomic changes using ultra-performance liquid chromatography (UPLC) quadrupole time-of-flight mass spectrometry (QTOF-MS) in serum samples of NHPs administered GT3. Our study, using 12 NHPs, demonstrates that alterations in metabolites manifest only 24 h after GT3 administration. Furthermore, metabolic changes are associated with transient increase in the bioavailability of antioxidants, including lactic acid and cholic acid and anti-inflammatory metabolites 3 deoxyvitamin D3, and docosahexaenoic acid. Taken together, our results show that the administration of GT3 to NHPs causes metabolic shifts that would provide an overall advantage to combat radiation injury. This initial assessment also highlights the utility of metabolomics and lipidomics to determine the underlying physiological mechanisms involved in the radioprotective efficacy of GT3. MDPI 2017-12-28 /pmc/articles/PMC5796029/ /pubmed/29283379 http://dx.doi.org/10.3390/ijms19010079 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cheema, Amrita K. Mehta, Khyati Y. Fatanmi, Oluseyi O. Wise, Stephen Y. Hinzman, Charles P. Wolff, Josh Singh, Vijay K. A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol |
title | A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol |
title_full | A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol |
title_fullStr | A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol |
title_full_unstemmed | A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol |
title_short | A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol |
title_sort | metabolomic and lipidomic serum signature from nonhuman primates administered with a promising radiation countermeasure, gamma-tocotrienol |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796029/ https://www.ncbi.nlm.nih.gov/pubmed/29283379 http://dx.doi.org/10.3390/ijms19010079 |
work_keys_str_mv | AT cheemaamritak ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT mehtakhyatiy ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT fatanmioluseyio ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT wisestepheny ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT hinzmancharlesp ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT wolffjosh ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT singhvijayk ametabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT cheemaamritak metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT mehtakhyatiy metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT fatanmioluseyio metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT wisestepheny metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT hinzmancharlesp metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT wolffjosh metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol AT singhvijayk metabolomicandlipidomicserumsignaturefromnonhumanprimatesadministeredwithapromisingradiationcountermeasuregammatocotrienol |